Patents Assigned to Merck
  • Aqueous coating solution for abrasion-resistant SiO2 antireflection layers
    Publication number: 20020090519
    Abstract: Aqueous coating solution having a pH of from 3 to 8, comprising 0.5-5.0% by weight of [SiOx(OH)y]n particles, where 0<y<4 and 0<x<2, having a particle size of from 10 nm to 60 nm with a tolerance of ±10%, and from 0.005 to 0.5% by weight, based on the coating solution, of a surfactant mixture obtainable by hydrolytic polycondensation of tetraalkoxysilanes in an aqueous-alcoholic-ammoniacal medium at temperatures between 35° C. and 80° C., with subsequent removal of ammonia and alcohol from the resultant dispersion by steam distillation and subsequent addition of a surfactant mixture comprising 15-30% by weight of anionic surfactants, 5-15% by weight of nonionic surfactants and less than 5% by weight of amphoteric surfactants.
    Type: Application
    Filed: October 18, 2001
    Publication date: July 11, 2002
    Applicant: Merck GmbH
    Inventors: Monika Kursawe, Walther Glaubitt
  • Method for producing ortho-alkylated benzoic acid derivatives
    Publication number: 20020091286
    Abstract: The invention relates to a process for the preparation of ortho-alkylated benzoic acid derivatives of the formula I 1
    Type: Application
    Filed: January 8, 2002
    Publication date: July 11, 2002
    Applicant: Merck GmbH
    Inventor: Ekkehard Bartmann
  • Liquid-crystalline medium
    Publication number: 20020090469
    Abstract: A liquid-crystalline medium based on a mixture of polar compounds of positive dielectric anisotropy, characterized in that it comprises one or more compounds of the formula I 1
    Type: Application
    Filed: October 19, 2001
    Publication date: July 11, 2002
    Applicant: Merck GmbH
    Inventors: Georg Lussem, Dagmar Klement, Volker Reiffenrath
  • Tetrakisfluoroalkylborate salts and their use as conducting salts
    Publication number: 20020090547
    Abstract: The present invention relates to tetrakisfluoroalkylborate salts, methods of producing same, and their use in electrolytes, batteries, capacitors, supercapacitors, and galvanic cells.
    Type: Application
    Filed: November 9, 2001
    Publication date: July 11, 2002
    Applicant: Merck Patent GmbH
    Inventors: Michael Schmidt, Andreas Kuhner, Helge Willer, Eduard Bernhardt
  • Formulations
    Patent number: 6417250
    Abstract: The present invention relates to formulations which essentially comprise a film-former or a casting resin and pearl lustre pigments which are coated with a silane of the formula I SiR1R2R3R4  I.
    Type: Grant
    Filed: August 21, 2001
    Date of Patent: July 9, 2002
    Assignee: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Manfred Kieser, Alfred Hennenmann
  • Process of preparing a multilayer cholesteric film I
    Patent number: 6417902
    Abstract: The invention relates to a process of preparing a multilayer cholesteric film comprising two or more layers of polymerized cholesteric liquid crystal (CLC) material with planar orientation, with the cholesteric helix axis oriented substantially perpendicular to the plane of the layer, wherein during preparation of the single layers the migration of unpolymerized material between adjacent layers is minimized, to a multilayer cholesteric film obtainable by such a process, and to the use of the process and a multilayer cholesteric film thereby prepared in optical elements such as polarizers, compensators, alignment layers, color filters or holographic elements, in cosmetics and liquid crystal pigments, for decorative and security applications.
    Type: Grant
    Filed: July 3, 2000
    Date of Patent: July 9, 2002
    Assignee: Merck Patent Gesellschaft
    Inventors: Simon Greenfield, Alison Linda May
  • Methods of identifying modulators of kinases responsive to stress
    Patent number: 6416964
    Abstract: The present invention relates to methods of identifying compounds useful as modulators of certain stress responsive kinases. More particularly, the compounds so identified are useful for treating or preventing diseases or conditions that are mediated by, for example, abnormal bone resorption or angiogenesis. These compounds are useful for treating or preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, and tumor growth.
    Type: Grant
    Filed: January 27, 1999
    Date of Patent: July 9, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Alfred A. Reszka, Gideon A. Rodan
  • Arylalkanoylpyridazines
    Patent number: 6417188
    Abstract: Arylalkanoylpyridazine derivatives of the formula I and their physiologically acceptable salts and solvates, in which R1, R2, Q and B have the meanings indicated in Claim 1, show an inhibition of phosphodiesterase IV and can be employed for the treatment of asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory diseases, autoimmune disorders, such as, for example, rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumor growth or tumor metastases, sepsis, memory disorders, atherosclerosis and AIDS.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: July 9, 2002
    Assignee: Merck Patent Gesellschaft mit beschraenkter Haftung
    Inventors: Rochus Jonas, Michael Wolf, Franz-Werner Kluxen
  • Prolines as antimicrobial agents
    Patent number: 6417217
    Abstract: Transfer ribonucleic acid (tRNA) synthetase inhibitors, salts, and pharmaceutically acceptable compositions thereof of the general formula: wherein Ar is aryl and heteroaryl; L is —C(O)N(Q)CH2—, or —CR10R11OCR12R13—; Q is hydrido, —(CH2)mCO2H and —(CH2)mCO2CH3, m is 1, 2, 3, and 4; R1, R2, R9, R10, R11, R12 and R13 are hydrido or lower alkyl; wherein Het is a heterocyclic moiety, the inhibitors are suitable for use as antimicrobial agents.
    Type: Grant
    Filed: August 22, 2001
    Date of Patent: July 9, 2002
    Assignees: Merck & Co., Inc., Cubist Pharmaceuticals, Inc.
    Inventors: Milton L. Hammond, Aaron H. Leeman, Milana Maletic, Gina M. Santorelli, Sherman T. Waddell, John Finn, Michael Morytko, Siya Ram, Dennis Keith
  • Liquid-crystal medium, and electro-optical display containing the medium
    Publication number: 20020084443
    Abstract: A liquid-crystal medium comprising a) at least one compound of the formula I and b) at least one compound of the formula II 1
    Type: Application
    Filed: March 26, 2001
    Publication date: July 4, 2002
    Applicant: Merck Patent GmbH
    Inventors: Michael Heckmeier, Dagmar Klement, Matthias Bremer
  • Liquid-crystal composition, methods of adjusting the resistance, and substituted phenols
    Publication number: 20020084444
    Abstract: The present invention relates to liquid-crystal mixtures having specific resistance values, comprising acidic compounds. The present invention furthermore relates to liquid-crystal displays containing these liquid-crystal mixtures.
    Type: Application
    Filed: July 19, 2001
    Publication date: July 4, 2002
    Applicant: Merck Patent Gesellschaft Mit
    Inventors: Michael Darius, Volker Reiffenrath, Kazuaki Tarumi, Bernhard Rieger, Michael Heckmeier, Marcus Reuter, Peer Kirsch
  • Text influenced molecular indexing system and computer-implemented and/or computer-assisted method for same
    Publication number: 20020087508
    Abstract: An extension of the vector space model for computing chemical similarity using textual and chemical descriptors is described. The method uses a chemical and/or textual description of a molecule/chemical and a decomposes a molecule/chemical descriptor matrix by a suitable technique such as singular value decomposition to create a low dimensional representation of the original descriptor space. Similarities between a user probe and the textual and/or chemical descriptors are then computed and ranked.
    Type: Application
    Filed: August 10, 2001
    Publication date: July 4, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Richard D. Hull, Eugene M. Fluder, Suresh B. Singh
  • Human metabotropic glutamate receptors, nucleic acids encoding same and uses thereof
    Patent number: 6413764
    Abstract: In accordance with the present invention, there are provided nucleic acids encoding human metabotropic glutamate receptor subtypes and the proteins encoded thereby. In a particular embodiment, the invention nucleic acids encode mGluR1, mGluR2, mGluR3 and mGluR5 subtypes of human metabotropic glutamate receptors. In addition to being useful for the production of metabotropic glutamate receptor subtypes, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits. In addition to disclosing novel metabotropic glutamate receptor subtypes, the present invention also comprises methods for using such receptor subtypes to identify and characterize compounds which affect the function of such receptors, e.g., agonists, antagonists, and modulators of glutamate receptor function.
    Type: Grant
    Filed: September 15, 1998
    Date of Patent: July 2, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Lorrie Daggett, Steven B. Ellis, Chen Liaw, Aaron Pontsler, Edwin C. Johnson, Stephen D. Hess
  • Cholesteric flakes
    Patent number: 6414092
    Abstract: The invention relates to cholesteric polymer flakes obtainable from a chiral polymerizable mesogenic material, to methods of manufacturing such cholesteric flakes, to the use of certain chiral and achiral polymerizable compounds with one or more terminal polymerizable groups for the manufacturing of such flakes and to the use of such cholesteric flakes as effect pigments in spraying or printing inks or paints or colored plastics for different applications, especially for automotive use, cosmetic products and security applications.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: July 2, 2002
    Assignee: Merck Patent Gesellschaft mit beschraenkter Haftung
    Inventors: David Coates, Mark Goulding, Alison May
  • Methods for inhibiting bone resorption
    Patent number: 6414006
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Grant
    Filed: October 13, 1999
    Date of Patent: July 2, 2002
    Assignees: Merck Frosst Canada & Co., Merck & Co., Inc.
    Inventors: Shun-ichi Harada, Gideon A. Rodan, Mohamed Machwate, Marc LaBelle, Kathleen Metters, Robert N. Young
  • Integrin receptor antagonists
    Patent number: 6413955
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.
    Type: Grant
    Filed: October 2, 2000
    Date of Patent: July 2, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Ben C. Askew, Garry R. Smith
  • Piperidinylmethyloxazolidinone derivative
    Patent number: 6413989
    Abstract: The invention relates to the compound 5-[4-(4-fluorobenzyl) piperidin-1-ylmethyl]-3-(4-hydroxy-phenyl)oxazolidin-2-one of the formula I and to physiologically acceptable salts thereof. The compound acts as a neuroleptic.
    Type: Grant
    Filed: May 17, 2000
    Date of Patent: July 2, 2002
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Helmut Prucher, Gerd Bartoszyk, Christoph Seyfried, Rudolf Gottschlich, Joachim Leibrock
  • Compositions and methods for inhibiting bone resorption
    Publication number: 20020082244
    Abstract: The present invention relates to oral compositions and methods for inhibiting bone resoprtion in a mammal while counteracting the occurrence of potentially adverse gastrointestinal effects. The compositions useful herein comprise the combination of a pharmaceutically effective amount of a nitrogen-containing bisphosphonate or a pharmaceutically-acceptable salt thereof and a pharmaceutically effective amount of an isoprenoid compound.
    Type: Application
    Filed: December 21, 2001
    Publication date: June 27, 2002
    Applicant: MERCK & Co., Inc.
    Inventors: Alfred A. Reszka, Edward S. Scolnick
  • Polysaccharide precipitation process
    Patent number: 6410025
    Abstract: Bacterial polysaccharides which are used to produced vaccines are isolated then precipitated with a long chain detergent. The precipitated polysaccharides are soluble in organic solvents and can be further derivatized and processed to form the vaccine.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: June 25, 2002
    Assignee: Merck & Co., Inc.
    Inventor: Russel J. Lander
  • Spiropiperidine derivatives as melanocortin receptor agonists
    Patent number: 6410548
    Abstract: Certain novel spiropiperidine compounds are agonists of melanocortin receptor(s) and are useful for the treatment, control or prevention of diseases and disorders responsive to the activation of melanocortin receptors. The compounds of the present invention are therefore useful for treatment of diseases and disorders such as obesity, diabetes, sexual dysfunction including erectile dysfunction and female sexual dysfunction.
    Type: Grant
    Filed: February 12, 2001
    Date of Patent: June 25, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Ravi P. Nargund, Zhixiong Ye, Brenda L. Palucki, Raman K. Bakshi, Arthur A. Patchett, Leonardus H. T. Van Der Ploeg